Aastrom Biosciences, Inc.

Ann Arbor, MI 48105

SBIR Award Summary

Total Number of Awards 30
Total Value of Awards $4.21MM
First Award Date 02/01/93
Most Recent Award Date 08/15/06

Key Personnel

Last Name Name Awards Contact
Armstrong R D Armstrong 1
Koller Manfred R Koller 2
Maluta James Maluta 2
Smith Douglas Matthew Smith 7
Smith Alan K Smith 5
Goltry Kristin L Goltry 10
Hampson Brian S Hampson 3

30 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/15/06 - 07/31/08

The therapeutic potential of patient-specific cultured cells continues to rapidly grow for a range of medical needs, such as regenerative repair of damaged tissue, cancer, and infectious diseases. As a result, the motivation to commercialize patient-specific "cell products" is increasing rapidly as well. A large unmet need exists for the develop...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/06 - 05/31/08

DESCRIPTION (provided by applicant): Due to morbidity and limited amounts of material, alternatives to autologous grafts for bone repair are desirable. Cells within the bone marrow are known to possess bone regenerative capacity, but they are limited in number. Increasing these osteoprogenitor cell populations through the use of ex vivo expansio...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/21/05 - 07/31/06

The therapeutic potential of patient-specific cultured cells continues to rapidly grow for a range of medical needs, such as regenerative repair of damaged tissue, cancer, and infectious diseases. As a result, the motivation to commercialize patient-specific "cell products" is increasing rapidly as well. A large unmet need exists for the develop...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/05 - 05/31/06

DESCRIPTION (provided by applicant): Due to morbidity and limited amounts of material, alternatives to autologous grafts for bone repair are desirable. Cells within the bone marrow are known to possess bone regenerative capacity, but they are limited in number. Increasing these osteoprogenitor cell populations through the use of ex vivo expansio...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/07/04 - 04/30/06

DESCRIPTION (provided by applicant): Tumor antigen primed dendritic cells (DCs) are under widespread clinical evaluation for immunotherapy of multiple forms of cancer. Emerging evidence suggests that DCs are fundamental regulators of the immune response leading to potent cell mediated immunity or alternatively to negative regulation and toleran...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-93
Budget: 07/01/04 - 06/30/06

DESCRIPTION (provided by applicant): Adherent mesenchymal cell populations derived from bone marrow (BM) have the capability of differentiating into multiple cell lineages in vitro and in vivo. The potential use of these populations, referred to as marrow stromal cells (MSC), in clinical applications to treat nonhematopoietic disorders is being ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 11/30/05

DESCRIPTION (provided by applicant): Malignant melanoma is a significant and deadly form of cancer worldwide. Emerging evidence has shown that melanoma cells express tumor-associated antigens that are specifically recognized by the immune system. Melanoma antigen-specific T-lymphocytes can be isolated from the tumors of late stage cancer patien...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-01-006
Budget: 09/30/03 - 10/31/04

DESCRIPTION (provided by applicant): Treatment of ischemia by administration of bone marrow (BM)-derived endothelial progenitor cells (EPC) or ex vivo expanded EPC populations has been shown to enhance vascular regeneration in animal models and in clinical trials. For cell therapy to be practical in a clinical setting, simple, efficient, GMP com...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/03 - 03/31/04

DESCRIPTION (provided by the applicant): Dendritic cells have been shown to initiate, regulate, and direct cytolytic T-cell-mediated immune responses against tumor antigens in human patients. Recent clincal trials have demonstrated induction of clinically significant immune responses against malignant diseases using DCs primed ex vivo with auto...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-93
Budget: 07/01/03 - 06/30/04

DESCRIPTION (provided by applicant): Adherent mesenchymal cell populations derived from bone marrow (BM) have the capability of differentiating into multiple cell lineages in vitro and in vivo. The potential use of these populations, referred to as marrow stromal cells (MSC), in clinical applications to treat nonhematopoietic disorders is being ...

Load More